An antidepressant is a psychoactive substance used in the pharmacological treatment of depressive disorders, with therapeutic benefit emerging only after weeks of continuous administration.[1] The class is defined by clinical function — amelioration of depressive symptomatology — rather than a single chemical scaffold or receptor target, so membership is broad and pharmacologically heterogeneous.
Conventional members modulate monoamine neurotransmission: SSRIs, SNRIs, MAOIs, and the tricyclic antidepressants each raise synaptic serotonin, norepinephrine, or both.[1] The three members loaded here — lithium, mirtazapine, and tianeptine — sit in the class's atypical and adjunctive wing, reaching the shared therapeutic endpoint through distinctly different molecular routes.
Antidepressants are used principally for major depressive disorder, with approved and off-label use spanning anxiety disorders, OCD, PTSD, panic disorder, insomnia, chronic pain, and migraine.[1] They generally do not produce an acute psychotropic effect at therapeutic doses; symptomatic relief consolidates gradually across weeks, and after sustained treatment abrupt cessation can precipitate a recognised discontinuation syndrome.[2]
Pharmacology
Most antidepressants converge on enhanced monoaminergic neurotransmission, though the three members loaded here reach the shared therapeutic endpoint by routes that depart from that template.[1]
| Mechanism | Representative member | How it reaches the shared endpoint |
|---|---|---|
| Noradrenergic and specific serotonergic antagonism (NaSSA) | mirtazapine | Blocks presynaptic α2-adrenergic auto- and heteroreceptors, disinhibiting serotonin and norepinephrine release; 5-HT2A/5-HT2C/5-HT3 antagonism channels available serotonin toward 5-HT1A[3] |
| μ-opioid receptor agonism | tianeptine | Full agonist at the human μ-opioid receptor and full δ-opioid receptor agonist at lower potency; opioid receptor activation is proposed as the primary molecular event underlying antidepressant and anxiolytic effect[4] |
| GSK-3 inhibition and CREB/BDNF potentiation | lithium | Inhibits glycogen synthase kinase-3 and inositol monophosphate signalling, disinhibiting CREB and potentiating BDNF expression alongside catecholamine and serotonin modulation[5] |
The mechanistic route matters less for the therapeutic timecourse than the downstream endpoint. Monoamine levels rise within hours of the first dose, but clinical benefit takes weeks — a delay that corresponds to the timeline of BDNF-dependent neuroplastic change.
Castrén and Antila propose that antidepressants increase BDNF expression and activate TrkB signalling, triggering a state of induced plasticity (iPlasticity) that reactivates developmental-period learning mechanisms in the adult brain; the several weeks required for newborn neurons to differentiate and integrate into functional circuits account for the therapeutic lag.[6]
Lithium's GSK-3 / CREB / BDNF route overlaps directly with this neuroplasticity hypothesis,[5] while tianeptine produces antidepressant effects without promoting hippocampal neurogenesis in the manner of conventional SSRIs — a meaningful mechanistic divergence within the class.[4]
Substances
The three members loaded here illustrate the class's atypical and adjunctive wing.
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Mirtazapine | NaSSA (atypical) | Strong H1-mediated sedation and appetite stimulation; minimal sexual dysfunction relative to SSRIs; clinically selected for comorbid insomnia or low body weight[3] |
| Tianeptine | Atypical (μ-opioid agonist) | Approved for depression in several European countries; opioid mechanism produces euphoria at supratherapeutic doses and confers physical-dependence liability; not FDA-approved in the United States[4] |
| Lithium | Mood stabiliser and antidepressant augmentation | Used primarily as augmentation in treatment-resistant depression; the strongest evidence of any class member for reducing suicide risk; narrow therapeutic index requiring mandatory serum monitoring[5] |
The members diverge sharply in receptor profile, tolerability, and monitoring requirements, but each reaches the shared therapeutic endpoint only after weeks of continuous use, each produces neurochemical adaptation that becomes clinically relevant on discontinuation, and each carries an interaction profile that must be managed clinically.
Subjective Effects
Antidepressants do not produce an acute psychotropic effect at therapeutic doses — the class's defining feature is a delayed therapeutic trajectory across weeks of continuous administration rather than an acute change in state.[1]
| Phase of treatment | Characteristic effects |
|---|---|
| Early | Activation effects — anxiety, insomnia, agitation, gastrointestinal upset — may emerge before mood improvement; sedating agents such as mirtazapine instead produce early somnolence and increased appetite[3] |
| Intermediate | Partial symptomatic relief begins; sleep and energy frequently improve before core mood symptoms; many initial adverse effects attenuate as tolerance develops |
| Sustained | Antidepressant benefit consolidates; depressed mood, anhedonia, cognitive slowing, and fatigue improve toward full response |
The class-wide safety hinge is that the same neurochemical adaptations that produce therapeutic benefit also generate an adapted state, so the longer treatment is sustained, the more cessation must be planned and tapered rather than abrupt.[2]
Within the class, individual agents carry their own acute profiles from the first dose. Mirtazapine's H1 antagonism produces sedation and increased appetite immediately and persistently.[3] Tianeptine at therapeutic doses lacks prominent acute psychoactive effects, but at supratherapeutic doses its μ-opioid activity produces opioid-like euphoria, analgesia, and anxiolysis.[4] Lithium at therapeutic serum levels is non-psychoactive in the conventional sense, though patients commonly report mild cognitive blunting.[5]
Safety
Risk profile
The most clinically significant acute danger across the class is serotonin syndrome — a potentially life-threatening toxidrome of neuromuscular hyperactivity (clonus, hyperreflexia, tremor), autonomic instability (diaphoresis, tachycardia, hyperthermia), and altered mental status, most commonly precipitated by combining two or more serotonergic agents.[7] The highest-risk combination is an MAOI taken concurrently with any other serotonergic antidepressant, including across an inadequately observed washout interval.
Outside the class, serotonin toxicity risk extends to combinations with tramadol, triptans, linezolid, methylene blue, and St. John's Wort.[7] Mirtazapine's 5-HT2 antagonism contributes to combination risk in certain regimens and its strong sedative profile potentiates other CNS depressants including alcohol and benzodiazepines.[3] Tianeptine's μ-opioid mechanism means concurrent opioid or CNS-depressant use compounds respiratory-depression risk.[4]
Antidepressants carry an FDA black-box warning for increased suicidal thinking and behaviour in paediatric and young-adult patients, with the risk profile reversing in older adults, in whom treatment appears protective.[1]
Lithium's narrow therapeutic index introduces a class-specific acute risk: toxicity is precipitated by dehydration, renal impairment, NSAIDs, thiazide diuretics, ACE inhibitors, or dose escalation without monitoring, and presents with tremor, nausea, and diarrhoea early, advancing to seizures, delirium, and cardiac arrhythmias in severe toxicity.[5] Regular therapeutic drug monitoring is not optional for lithium.
Tolerance & dependence
Tolerance to therapeutic effect ("tachyphylaxis" or "poop-out") develops in a proportion of patients on long-term therapy, manifesting as a gradual return of depressive symptoms despite maintained dosing. Tolerance to adverse effects such as nausea and sedation also commonly develops in the first weeks of treatment, which is clinically useful.
Dependence varies sharply across the class. Tianeptine carries the most significant dependence liability of the loaded members: its opioid mechanism produces physical dependence consistent with other opioid agonists, with dose escalation, craving, and characteristic opioid withdrawal on abrupt cessation.[4] Lithium does not produce addiction-type dependence, but abrupt cessation after long-term use can precipitate rebound mania or depression.[5] Mirtazapine produces a recognised discontinuation syndrome on abrupt cessation, though conventional addiction-sense dependence is not established.
Recovery
Recovery from depression and from antidepressant treatment is well-trodden clinical territory. Sustained treatment is typically maintained for at least 6–12 months after remission — and often longer in recurrent illness — before discontinuation is attempted, and lithium augmentation is generally continued for approximately a year after remission of a treatment-resistant episode before gradual withdrawal is considered.[5]Discontinuation should be planned with a prescribing clinician, with gradual dose tapering tailored to the agent's half-life and the individual response.[2] Tianeptine dependence follows an opioid-dependence recovery model — gradual taper, potentially with opioid substitution therapy, and monitoring for withdrawal — qualitatively different from the discontinuation trajectory of the other loaded members.[4] A prescribing clinician or a specialist withdrawal-management service can structure a safe plan.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1]
- [2]^abcdHenssler, J. and Schmidt, Y. and Schmidt, U. and Schwarzer, G. and Bschor, T. and Baethge, C. (2024) Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis — The Lancet Psychiatry doi:10.1016/s2215-0366(24)00133-0
- [3]
- [4]
- [5]
- [6]^Castrén, E. and Antila, H. (2017) Neuronal plasticity and neurotrophic factors in drug responses — Molecular Psychiatry doi:10.1038/mp.2017.61